Nerve Block vs Local Anesthetic for Postoperative Pain
Trial Summary
The trial information does not specify if you need to stop taking your current medications. However, if you are opioid tolerant or have narcotic dependence, you may not be eligible to participate.
Research shows that the erector spinae plane block can effectively reduce pain after lumbar spinal surgery, as it has been compared favorably to wound infiltration and shown to improve pain relief in various studies.
12345The available research does not specifically address the safety of the Erector Spinae Plane (ESP) Block, but it is a widely used technique for managing pain after surgery, suggesting it is generally considered safe in clinical practice.
14678The erector spinae plane block is a novel regional anesthesia technique that involves injecting a local anesthetic near the spine to block pain signals. Unlike traditional methods, it targets the origin of spinal nerves and can be used for a wide range of surgeries, offering a potentially safer and more effective alternative for managing postoperative pain.
256910Eligibility Criteria
This trial is for adults aged 18-80 who have not regularly used opioids (less than the equivalent of 6 oxycodone pills per day), are undergoing a planned non-emergency spinal fusion surgery between T8 and S2, and have no allergies or conditions that would prevent them from receiving local anesthetics or regional anesthesia procedures.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-procedure
Pre-procedure activities include survey evaluations and baseline evaluations such as social history, pain medication history, and pain rating
Treatment
Participants undergo thoraco-lumbar fusion surgery with different anesthesia protocols: ESP block, LIA, or GA only
Post-operative Monitoring
Pain control and opioid usage are monitored for the first 72 hours post-surgery, with survey evaluations during the first 7 days of hospital stay
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of delirium symptoms up to 3 days post-operation